American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463, 15 August 2009

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • Corresponding Author InformationCorresponding author: Tel: 45-7527-9072; Fax: 45-7527-9072
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Rana Fayyad, PhD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Sonal Bhatia, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Scott M. Grundy, MD, PhD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • John C. LaRosa, MD

      Affiliations

    • State University of New York Health Science Center, Brooklyn, New York
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer, Sweden, Sollentuna, Sweden
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • David D. Waters, MD

      Affiliations

    • San Francisco General Hospital, San Francisco, California
    • ,
  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Steering Committees of the IDEAL and TNT Trials

Received 13 January 2009; received in revised form 11 April 2009; accepted 11 April 2009. published online 26 June 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The IDEAL and TNT studies were sponsored by Pfizer, Inc., New York, New York.

PII: S0002-9149(09)00910-2

doi:10.1016/j.amjcard.2009.04.008

American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463, 15 August 2009

Article Tools

* Image Usage & Resolution